RBM34 (RNA binding motif protein 34) is an RNA-binding protein primarily localized to the nucleus with demonstrated roles in post-transcriptional gene regulation and cancer biology 1. While GO annotations suggest involvement in ribosomal RNA maturation, particularly LSU-rRNA processing in the nucleolus, the provided abstracts focus predominantly on RBM34's cancer-related functions rather than its canonical rRNA processing role. Mechanism: RBM34 functions as a trans-acting regulator of gene expression. It participates in regulatory networks with other RNA-binding proteins (CMSS1 and DDX5) to modulate hTERT expression in non-small cell lung cancer cells, affecting mRNA stability and cancer cell progression 2. RBM34 exhibits differential splice isoforms with distinct functional network properties and tissue-specific expression patterns 3. Disease Relevance: RBM34 is differentially expressed across multiple human cancer types and serves as an independent prognostic factor for osteosarcoma 1. Expression levels significantly correlate with tumor-infiltrating lymphocyte populations, immunomodulatory molecules, and immunotherapy response biomarkers 1. RBM34 was identified as a predictive feature in melanoma survival models incorporating immunotherapy response 4. Additionally, RBM34 expression is significantly reduced in African American males living in poverty, correlating with altered PBMC gene expression patterns associated with health disparities 5. Clinical Significance: RBM34 represents a viable therapeutic target for osteosarcoma and potentially other cancers, with prognostic utility for predicting patient outcomes and immune landscape estimation.